GLP-1 acts to inhibit cardiac remodeling and cardiomyocyte apoptosis pathways, which can help repair cardiac dysfunction [8, 9]
While this design strategy enhances histologic signal detection, it may under-represent non-obese MASLD or earlier-stage fibrosis phenotypes typically encountered in community practice, ultimately limiting the generalizability of these findings to the broader MASLD spectrum
Further studies are needed to confirm the central protective effect of GLP-1 RA, and further clinical trials should be actively conducted
In fact, Wegovy was studied specifically for weight loss, and the FDA approved the drug for weight loss in people 12 years and older
They do not replace evaluation of a new smell, especially when ketones, dehydration, or infection are on the table
doi: 10.1007/s00394-020-02248-7 29 BeserraBTFernandesRdo RosarioVAMocellinMCKuntzMGTrindadeEB